• Peter Minetti has been promoted by Fujirebio Diagnostics (FDI; Malvern, Pennsylvania) to serve as vice president of quality and regulatory compliance. Minetti joined FDI in 2000 and assumed responsibility for managing all elements of FDI's quality system. FDI specializes in in vitro diagnostic products for the management of human disease states, with an emphasis in oncology.

• Andrew Chisholm has been named director of corporate accounts for HemoSense (San Jose, California). Prior to joining HemoSense, Chisholm managed sales and marketing activities with increasing responsibility at Bayer Healthcare, Henry Schein, Johnson & Johnson and Eastman Kodak. HemoSense is focused on point-of-care blood coagulation diagnostics.

• Ron Wheet has been named CEO and chairman of the board of Maxxon (Tulsa, Oklahoma), replacing Gifford Mabie Jr., who has resigned as CEO and a director. Wheet is a director of the company and is president of Osprey South. Maxxon is a development-stage company focused on reducing the risk of accidental needlestick injuries and deaths. The company's 3 cc safety syringe, presently in development, is designed as a single-handed, vacuum-operated safety syringe that retracts the used needle into the syringe after use.

• Donald Monack, executive vice president and chief development officer, is resigning from National Mentor Holdings (Boston), effective March 31. Monack joined The Mentor Network in 1989 as national business director. National Mentor Holdings, marketing its services under the name The Mentor Network, is a provider of home and community-based human services for individuals with mental retardation and other developmental disabilities, at-risk youth and persons with acquired brain injury.